Davis Polk advised the representatives of the underwriters in connection with the $175 million public offering by Cellectis S.A. of 5,646,000 American Depositary Shares, each representing one ordinary share. Cellectis has granted the underwriters an option to purchase up to an additional 846,900 ADSs. The ordinary shares are listed on the Euronext Growth Market of Euronext in Paris under the symbol “ALCLS” and the ADSs are listed on the NASDAQ Global Market under the symbol “CLLS.”

Based in France, Cellectis is a clinical stage biotechnological company, employing its core proprietary technologies to develop best-in-class products in the field of immuno-oncology. Its product candidates, based on gene-edited T-cells that express chimeric antigen receptors seek to harness the power of the immune system to target and eradicate cancer cells.

The Davis Polk corporate team included partner Richard D. Truesdell Jr. and associates Kate Darracott and Yoojin L. Kim. Counsel Juliette Loget and associate Géraldine Fromage provided French law advice. Counsel David R. Bauer and associates Bonnie Chen and Jay Frankel provided intellectual property and technology advice. Partner Mario J. Verdolini and associate Liang Zhang provided tax advice. Members of the Davis Polk team are based in the New York, Paris and London offices.

Copy link to share post